Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
American chemical industry news
(page 3)
20 April 2026
PPG launches first U.S. PVC-NI coil coating for aluminum pet food cans
One-component PVC-NI coil-applied interior coating for aluminum DRD cans and easy-open ends; ready, cuts changeovers and waste, cures across lines, resists stains in wet pet food; brand-approved.
20 April 2026
Lilly to acquire Kelonia Therapeutics for in vivo CAR‑T platform
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.
20 April 2026
Merck: FDA grants priority review for KEYTRUDA/KEYTRUDA QLEX with Padcev in cisplatin‑eligible MIBC
FDA granted priority review for two sBLAs after Phase 3 KEYNOTE‑B15 showed EFS and OS benefit; PDUFA Aug 17, 2026. If approved, first perioperative options for MIBC regardless of cisplatin eligibility.
20 April 2026
Perpetual Next hires GLS for U.S. biomethanol site selection
Consultant to assess U.S. candidate sites and feedstock markets, compare torrefaction, biomethanol and integrated concepts, and deliver evidence-based site-selection reports with risks and next steps.
20 April 2026
Novo Nordisk: Etavopivat meets phase‑3 HIBISCUS endpoints — reduces VOCs and increases haemoglobin in sickle cell disease
HIBISCUS phase‑3 (n=385, ≥12 yrs): etavopivat cut VOCs by 27% and delayed first VOC ~4 months; 48.7% had >1 g/dL Hb rise at 24 weeks vs 7.2% placebo. Well tolerated; filing H2 2026.
20 April 2026
PPG installs radiation-curing test line in Marly, France
New Marly R&D line tests IR, UV (LED, excimer, arc) and EB curing to replicate production, speed development, cut customer trials, and reduce energy use and VOCs.
How does the American chemical industry perform?
Find out with
chemXplore Alpha
Learn more
20 April 2026
Asahi Kasei Acquires Aicuris to Expand Infectious-Disease Pharma Portfolio
Acquisition adds three antiviral assets - royalties from Prevymis, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 - aims $500M revenue by 2030 and transplant/infectious-disease growth.
20 April 2026
GSK's Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma
Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
20 April 2026
Heidelberg Materials takes 79.44% majority stake in Akçansa
Strengthens presence in Turkey and the Med; integrated cement, concrete, quarries and ports to unlock operational/logistical synergies and expand exports to the Black Sea and US East Coast.
20 April 2026
Siemens launches Eigen Engineering Agent for autonomous industrial engineering
Moves industrial AI from assistance to autonomous execution—plans, codes, configures and validates systems. Pilots report 2–5× faster delivery, up to 50% efficiency gains and higher solution quality.
17 April 2026
Siemens showcases industrial AI transforming manufacturing at Hannover Messe
Shows industry AI and digital twins: robotics, pop-up mini‑factory for CPG value chains, autonomous 3D‑printing with AI agents and robots, plus DC power‑grid tech for data centers
16 April 2026
Repsol to raise oil production in Venezuela
Agreed with Venezuela and PDVSA to resume Petroquiriquire operations, ensure payments and raise output 50% in 12 months and 3x in 3 years if conditions hold; OFAC GL50A permits transactions.
16 April 2026
Lilly ACHIEVE‑4 confirms Foundayo cardiovascular safety and cardiometabolic benefits
ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.
15 April 2026
PPG acquires pavement-marking maker Ozark Materials
All-cash $65M purchase of a U.S. pavement-marking supplier serving US and Canada. About 130 employees; strengthens Traffic Solutions and North American market presence.
15 April 2026
Boehringer Ingelheim & Zai Lab launch DLL3‑targeting T‑cell engager + ADC trial in SCLC and NECs
Phase Ib/II testing obrixtamig (DLL3/CD3 T‑cell engager) plus zoci (zocilurtatug pelitecan, DLL3 ADC) in ES‑SCLC and other NECs to assess safety, tolerability and early clinical activity
14 April 2026
Dow appoints Karen S. Carter CEO; Jim Fitterling becomes Executive Chair
Effective July 1, 2026, Jim Fitterling shifts from CEO to Executive Chair; COO Karen S. Carter succeeds him as CEO and joins the board after a multi-year succession plan.
14 April 2026
Genmab: DARZALEX Q1 2026 net sales USD 3,964m
DARZALEX Q1 sales split: US $2,208m; RoW $1,756m. Includes subcutaneous FASPRO in U.S. Royalties received under J&J exclusive license.
14 April 2026
WACKER and Amyris partner on bio-based personal-care ingredients
Develop bio-based functional ingredients for cosmetics; expand silicone range with renewable raw materials; test novel molecules and production integration.
14 April 2026
Novo Nordisk partners with OpenAI to speed drug discovery and delivery
Integrate advanced AI across drug discovery, manufacturing, supply chain and commercial ops to speed development, upskill staff; pilots now, full integration by end-2026; strict governance.
14 April 2026
OCI Global sells 2M Methanex shares for ~$116.6M
Block trade on 13 April; ownership fell from ~6.0% to ~3.4%. Transaction was for investment purposes; company may repurchase or further sell shares depending on market and the stock's performance.
14 April 2026
AGC Pharma Chemicals named Best-in-Class in four CDMO Leadership Awards 2026 categories
Selected via client evaluations and Tufts CSDD, praised for specialized staff, cultural fit, tech use and scaling support; offers cGMP CDMO services across Japan, US, EU and supports varied modalities
13 April 2026
Clariant launches Hostapon CT solid, a salt-free mild taurate surfactant
New surfactant offers 90% actives, long-lasting silky foam, strong oil stability, low-salt formulation flexibility, mildness for dry/sensitive skin, 80% RCI and ready biodegradability.
13 April 2026
Lucas Meyer Cosmetics by Clariant unveils AlgaSurge, Lysofix Liquid and LightYears at in-cosmetics 2026
Introduces a microalgae skin longevity active that boosts hydration, collagen and renewal, and reduces inflammation and spots. Emulsifier data: soothes, repairs barrier and improves hair combing.
13 April 2026
Honeywell to supply liquefaction technology for Rio Grande LNG Trains 4–5
NextDecade will use CWHE and C3MR via Bechtel to boost reliability, cut OPEX and increase LNG output from 18 to 30 MTPA; all five trains expected online by mid-2031.
13 April 2026
Genmab: Rina‑S plus bevacizumab tolerable in advanced ovarian cancer
RAINFOL‑01 D2 (n=40): common TEAEs—nausea 80%, fatigue 67.5%, anemia 55%, neutropenia 45%; serious TEAEs 15%; dose reductions 27.5%; no fatal TEAEs. Phase 3 RAINFOL‑04 ongoing.
13 April 2026
Daiichi Sankyo and Merck: FDA Priority Review for Ifinatamab Deruxtecan in ES‑SCLC
BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).
13 April 2026
Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026
12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins
13 April 2026
Lilly: Jaypirca plus venetoclax‑rituximab extends PFS in previously treated CLL/SLL
Phase 3 BRUIN CLL-322 (n=639) in relapsed/refractory CLL/SLL: time-limited (2-yr) pirtobrutinib with venetoclax+rituximab showed consistent benefit across subgroups; safety similar; OS immature.
13 April 2026
Roche's Elecsys NfL CE‑marked to monitor neuroinflammation in RRMS
New blood test detects neuroaxonal damage, enabling minimally invasive, more accessible monitoring of neuroinflammation, complementing MRI and supporting earlier clinical intervention
10 April 2026
Johnson & Johnson: TECNIS PureSee IOL Shows Strong Contrast Sensitivity and Extended Range of Vision
Real-world and randomized trials show excellent distance/intermediate vision, some near gain, high satisfaction, low visual disturbances and strong tolerance to residual refractive error.
← Previous
Next →
